Biotech Company To Combat Tumor Growth

A biotechnology company spun off from University of Arizona research hopes to commercialize methods to stunt blood-vessel growth in tumors. The research under a National Institutes of Health (news - web sites) grant has shown that a growth regulator called apelin is a potent stimulator of blood-vessel growth, said Paul A. Krieg, a professor who formed Angionics Inc. recently. "What we're hoping as a startup company is that maybe by blocking the apelin, we may also block the tumor," said Krieg, who works in the university's department of cell biology and anatomy.

Back to news